NEW YORK, March 6, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 9980.
The investigation concerns whether Ionis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On March 6, 2017, pre-market, Ionis's subsidiary Akcea Therapeutics disclosed data from a Phase 3 study of volanesorsen, an experimental therapy for familial chylomicronemia syndrome, showing that 10 of the 66 patients included in the study had discontinued treatment. Five patients discontinued the therapy because of injection site reactions, while another five patients discontinued due to platelet declines. The Company reported eight serious adverse events associated with volanesorsen.
On this news, Ionis's share price has fallen as much as $4.55, or 8.32%, during intraday trading on March 6, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ionis-pharmaceuticals-inc--ions-300418444.html
SOURCE Pomerantz LLP